Androgen deficiency and atherosclerosis: The lipid link

Vascular Pharmacology

Volumn 51, Issue 5-6, 2009, Pages 303-313

  Traish, Abdulmaged M ^a   Abdou, Rami ^a   Kypreos, Kyriakos E ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Androgen deficiency; Androgen therapy; Atherosclerosis; Cardiovascular Disease; Dyslipidemia; HDL; LDL; Metabolic syndrome; Testosterone

Indexed keywords

ANDROGEN RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; HEART PROTECTION; HUMAN; LIPID METABOLISM; LIPID TRANSPORT; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL, HDL; HUMANS; LIPOPROTEINS; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 70449134616     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.09.003     Document Type: Review

References (146)

1. Agledahl I., Skjaerpe P.A., Hansen J.B., and Svartberg J. Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromso study. Nutr. Metab. Cardiovasc. Dis. 18 (2008) 256-262
2. Akishita M., Hashimoto M., Ohike Y., Ogawa S., Iijima K., Eto M., and Ouchi Y. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens. Res. 30 (2007) 1029-1034
3. Alibhai S.M., Duong-Hua M., Sutradhar R., Fleshner N.E., Warde P., Cheung A.M., and Paszat L.F. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. 27 (2009) 3452-3458
4. Allan C.A., Strauss B.J.G., Burger H.G., Forbes E.A., and McLachlan R.I. Testosterone therapy prevents gain in adipose tissue and loss of skeletal muscle in nonobese aging men. J. Clin. Endocrinol. Metab. 93 (2008) 139-146
5. Bagatell C.J., Heiman J.R., Matsumoto A.M., Rivier J.E., and Bremner W.J. Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 79 (1994) 561-567
6. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann. Intern. Med. 117 (1992) 807-811
7. Barrett-Connor E., and Khaw K.T. Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78 (1988) 539-545
8. Barud W., Palusinski R., Beltkowski J., and Wojcicka G. Inverse relationship between total testosterone and anti-oxidized low-density lipoprotein antibody levels in ageing males. Atherosclerosis 164 (2002) 282-288
9. Basaria S., and Dobs A.S. Testosterone making an entry into the cardiometabolic world. Circulation 116 (2007) 2658-2661
10. Beigneux A.P., Davies B.S., Gin P., Weinstein M.M., Farber E., Qiao X., Peale F., Bunting S., Walzem R.L., Wong J.S., Blaner W.S., Ding Z.M., Melford K., Wongsiriroj N., Shu X., de Sauvage F., Ryan R.O., Fong L.G., Bensadoun A., and Young S.G. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 5 (2007) 279-291
11. Beigneux A.P., Franssen R., Bensadoun A., Gin P., Melford K., Peter J., Walzem R.L., Weinstein M.M., Davies B.S., Kuivenhoven J.A., Kastelein J.J., Fong L.G., Dallinga-Thie G.M., and Young S.G. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler. Thromb. Vasc. Biol. 29 (2009) 956-962
12. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 1299-1305
13. Blouin K., Despres J.P., Couillard C., Tremblay A., Prud'homme D., Bouchard C., and Tchernof A. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 54 (2005) 1034-1040
14. Blouin K., Boivin A., and Tchernof A. Androgens and body fat distribution. J. Steroid Biochem. Mol. Biol. 108 (2008) 272-280
15. Braga-Basaria M., Muller D.C., Carducci M.A., Dobs A.S., and Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int. J. Import. Res. 18 (2006) 494-498
16. Brown W.V., and Baginsky M.L. Inhibition of lipoprotein lipase by an apoprotein of human very low-density lipoprotein. Biochem. Biophys. Res. Commun. 46 (1972) 375-382
17. Chen K.C., Peng C.C., Hsieh H.M., Peng C.H., Hseih C.L., Hunag C.N., Chyau C.C., Wang H.E., and Peng R.Y. Antiandrogenic therapy can cause coronary arterial disease. Int. J. Urol. 12 (2005) 886-891
18. D'Amico A., Denham J., Crook J., Chen M.H., Goldhaber S., Lamb D., Joseph D., Tai K.H., Malone S., Ludgate C., Steigler A., and Kantoff P. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25 (2007) 2420-2425
19. Debing E., Peeters E., Duquet W., Poppe K., Velkeniers B., and Van Den Brande P. Men with atherosclerotic stenosis of the carotid artery have lower testosterone levels compared with controls. Int. Angiol. 27 (2008) 135-141
20. Demirbag R., Yilmaz R., Ulucay A., and Unlu D. The inverse relationship between thoracic intima media thickness and testosterone level. Endocr. Res. 31 (2005) 335-344
21. Derby C.A., Zilber S., Brambilla D., Morales K.H., and McKinlay J.B. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Aging Study. Clin. Endocrinol. 65 (2006) 125-131
22. Dobs A.S., Bachorik P.S., Arver S., Meikle A.W., Sanders S.W., Caramelli K.E., and Mazer N.A. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J. Clin. Endocrinol. Metab. 86 (2001) 1026-1033
23. Dockery F., Bulpitt C.J., Agarwal S., Donaldson M., and Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin. Sci. 104 (2003) 195-201
24. Efstathiou J.A., Bae K., Shipley W.U., Hanks G.E., Pilepich M.V., Sandler H.M., and Smith M.R. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur. Urol. 54 (2008) 816-823
25. Efstathiou J.A., Bae K., Shipley W.U., Hanks G.E., Pilepich M.V., Sandler H.M., and Smith M.R. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J. Clin. Oncol. 27 (2009) 92-99
26. Emmelot-Vonk M.H., Verhaar H.J.J., Nakhai Pour H.R., Aleman A., Lock T.M.T.W., Ruud Bosch J.L.H., Grobbee D.E., and van der Schouw Y.T. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older age. A randomized controlled trial. J. Amer. Med. Assoc. 299 (2008) 39-52
27. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Immunol. 115 (2005) 911-919
28. Fazio S., Linton M.F., Hasty A.H., and Swift L.L. Recycling of apolipoprotein E in mouse liver. J. Biol. Chem. 274 (1999) 8247-8253
29. Finch C.E., and Morgan T.E. Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr. Alzheimer's Res. 4 (2007) 185-189
30. Fitzgerald M.L., Morris A.L., Chroni A., Mendez A.J., Zannis V.I., and Freeman M.W. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J. Lipid Res. 45 (2004) 287-294
31. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., Sethi A.A., Remaley A.T., Schnohr P., Grande P., and Tybjaerg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 299 (2008) 2524-2532
32. Fu L., Gao Q.P., and Shen J.X. Relationship between testosterone and indexes indicating endothelial function in male coronary heart disease patients. Asian J. Androl. 10 (2008) 214-218
33. Fukui M., Kitagawa Y., Nakamura N., Mogami S., Hirata C., Ichio N., Wada K., Hasegawa G., and Yoshikawa T. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care 26 (2003) 1869-1873
34. Fukui M., Kitagawa Y., Ose H., Hasegawa G., Yoshikawa T., and Nakamura N. Role of endogenous androgen against insulin resistance and atherosclerosis in men with type 2 diabetes. Curr. Diabetes Rev. 3 (2007) 25-31
35. Fukui M., Ose H., Kitagawa Y., Yamazaki M., Hasegawa G., Yoshikawa T., and Nakamura N. Relationship between low serum endogenous androgen concentrations and arterial stiffness in men with type 2 diabetes mellitus. Metabolism 56 (2007) 1167-1173
36. Goralski K.B., and Sinal C.J. Type II diabetes and cardiovascular disease: getting to the fat of the matter. Can. J. Physiol. Pharm. 85 (2007) 113-132
37. Groop L., and Orho-Melander M. The dysmetabolic syndrome. J. Intern. Med. 250 2 (2001) 105-120
38. Haddad R.M., Kennedy C.C., Caples S.M., Tracz M.J., Bolona E.R., Sideras K., Uraga M.V., and Erwin P.J. Montori. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin. Proc. 82 (2007) 29-39
39. Hadi H.A., Carr C.S., and Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc. Risk Manag. 1 (2005) 183-198
40. Haffner S.M., Mykkänen L., Valdez R.A., and Katz M.S. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J. Clin. Endocrinol. Metab. 77 (1993) 1610-1615
41. Haidar A., Yassin A., Saad F., and Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. Aging Male 10 (2007) 189-196
42. Hak A.E., Witteman J.C., de Jong F.H., Geerlings M.I., Hofman A., and Pols H.A. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J. Clin. Endocrinol. Metab. 87 (2002) 3632-3639
43. Hanks G.E., Pajak T.F., Porter A., Grignon D., Brereton H., Venkatesan V., Horwitz E.M., Lawton C., Rosenthal S.A., Sandler H.M., Shipley W.U., and Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. 21 (2003) 3972-3978
44. Hasty A.H., Linto M.F., Swift L.L., and Fazio S. Determination of the lower threshold of apolipoprotein E resulting in remnant lipoprotein clearance. J. Lipid Res. 40 (1999) 1529-1538
45. Hauner H. Insulin resistance and the metabolic syndrome-a challenge of the new millennium. Eur. J. Clin. Nutr. 56 (2002) 25-29
46. Herbst K.L., Amory J.K., Brunzell J.D., Chansky H.A., and Bremner W.J. Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. Am. J. Physiol. Endocrinol. Metab. 284 (2003) E1112-E1118
47. Hersberger M., Muntyler J., Funke H., Marti-Jaun J., Schulte H., Assmann G., Luscher T.F., and von Eckardstein A. The CAG repeat polymorphism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction. Clin. Chem. 51 (2005) 1110-1115
48. Hessler J.R., Robertson A.L., and Chisolm G.M. LDL indiced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32 (1979) 213-229
49. Howell S.J., Radford J.A., Adams J.E., et al. Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin. Endocrinol. 55 (2001) 315-324
50. Isidori A.M., Giannetta E., Pozza C., Bonifacio J., and Isidori A. Androgens, cardiovascular disease and osteoporosis. J. Endocrinol. Invest. 28 (2005) 73-79
51. Jin H., Qiu W.B., Mei Y.F., Wang D.M., Li Y.G., and Tan X.R. Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor downregulation via suppression of nuclear factor-kappa B in endothelial cells. Asian J. Androl. 11 (2009) 266-271
52. Jones T.H. Advances in the management of testosterone deficiency. Front. Horm. Res. 37 (2009) 1-4
53. Jones, T.H., Saad, F., in press. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis (Apr 24, Electronic publication ahead of print). PMID: 19464009 (PubMed - as supplied by publisher).
54. Jones R.D., Nettleship J.E., Kapoor D., Jones H.T., and Channer K.S. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am. J. Cardiovasc. Drugs 5 (2005) 141-154
55. Kalyani R.R., and Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr. Opin. Endocrinol. Diabetes Obes. 14 (2007) 226-234
56. Kapoor D., and Jones T.H. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for investigation?. Drugs Aging 25 (2008) 357-369
57. Karagiannides I., Abdou R., Tzortzopoulou A., Voshol P.J., and Kypreos K.E. Apolipoprotein E predisposes to obesity and related metabolic dysfunctions in mice. FEBS J. 275 (2008) 4796-4809
58. Kaufman J.M., and Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26 (2005) 833-876
59. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24 (2006) 4448-4456
60. Khaw K., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., and Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116 (2007) 2694-2701
61. Kintzel P.E., Chase S.L., Schultz L.M., and O'Rourke T.J. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy 28 (2008) 1511-1522
62. Kortz W.J., Schirmer B.D., Mansbach C.M., Shelburne F., Toglia M.R., and Quarfordt S.H. Hepatic uptake of chylomicrons and triglyceride emulsions in rats fed diets of differing fat content. J. Lipid Res. 25 (1984) 799-804
63. Kypreos K.E. ABCA1 promotes the do novo genesis to apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia. Biochemistry 47 (2008) 10491-10502
64. Kypreos K., and Zannis V. LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J. Lipid Res. 47 (2006) 521-529
65. Kypreos K., and Zannis V. Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem. J. 403 (2007) 359-367
66. Lambert G., Chase M.B., Dugi K., Bensadoun A., Brewer Jr. H.B., and Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J. Lipid Res. 40 (1999) 1294-1303
67. Langer C., Gansz B., Goepfert C., Engel T., Uehara Y., von Dehn G., Jansen H., Assmann G., and von Eckardstein A. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem. Biophys. Res. Commun. 296 (2002) 1051-1057
68. Linton M.F., and Fazio S. Macrophages, lipoprotein metabolism, and atherosclerosis: insights from murine bone marrow transplantation studies. Curr. Opin. Lipidol. 10 (1999) 97-105
69. Liu B., and Krieger M. Highly purified scavenger receptor class B, type I reconstituted into phosphatidylcholine/cholesterol liposomes mediates high affinity high density lipoprotein binding and selective lipid uptake. J. Biol. Chem. 277 (2002) 34125-34135
70. Liu T., Krieger M., Kan H.Y., and Zannis V.I. The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport. J. Biol. Chem. 277 (2002) 21576-21584
71. Lu Y.L., Kuang L., Zhu H., Wu H., Wang X.F., Pang Y.P., Wang N.J., and Yu D.L. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5-alpha-reductase inhibitor. Asian J. Androl. 9 (2007) 843-847
72. Ly L.P., Jimenez M., Zhuang T.N., Celermajer D.S., Conway A.J., and Handelsman D.J. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J. Clin. Endocrinol. Metab. 86 (2001) 4078-4088
73. Maison P., Byrne C.D., Hales C.N., Day N.E., and Wareham N.J. Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 24 (2001) 1758-1763
74. Mäkinen J., Jarvisalo M., Pollanen P., Perheentupa A., Irjala K., Koskenvuo M., Mäkinen J., Huhtaniemi I., and Raitakari O. Increased carotid atherosclerosis in andropausal middle-aged men. J. Am. Coll. Cardiol. 45 (2005) 1603-1608
75. Malkin C.J., Pugh P.J., Jones R.D., Jones T.H., and Channer K.S. Testosterone as a protective factor against atherosclerosis-immunomodulation and influence upon plaque development and stability. J. Endocrinol. 178 (2003) 373-380
76. Malkin C.J., Pugh P.J., Jones R.D., Kapoor D., Channer K.S., and Jones T.H. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J. Clin. Endocrinol. Metab. 89 (2004) 3313-3318
77. Mann C.J., Yen F.T., Grant A.M., and Bihain B.E. Mechanisms of plasma cholesterol ester transfer in hypertriglyceridemia. J. Clin. Invest. 88 (1991) 2059-2066
78. McRobb L., Handelsman D.J., and Heather A.K. Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. Endocrinology 150 (2009) 841-848
79. Muller M., van den Deld A.W., Bots M.L., Grobbee D.E., Lamberts S.W., and van der Schouw Y.T. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109 (2004) 2074-2079
80. Navab M., Imes S.S., Hama S.Y., Hough G.P., Ross L.A., Bork R.W., Valente A.J., Berliner J.A., Drinkwater D.C., Laks H., and Fogelman A.M. Monocyte transmigration induced by modification of low-density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high-density lipoprotein. J. Clin. Invest. 88 (1991) 2039-2046
81. Nettleship J.E., Pugh P.J., Channer K.S., Jones T., and Jones R.D. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm. Metab. Res. 39 (2007) 366-371
82. Nettleship J.E., Jones T.H., Channer K.S., and Jones R.D. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation. 116 (2007) 2427-2434
83. Nettleship J.E., Jones R.D., Channer K.S., and Jones T.H. Testosterone and coronary artery disease. Front. Horm. Res. 37 (2009) 91-107
84. Ng M.K. New perspectives on Mars and Venus: unraveling the role of androgens in gender differences in cardiovascular biology and disease. Heart Lung Circ. 16 (2007) 185-192
85. Nishida H.I., Nakanishi T., Yen E.A., Arai H., Yen F.T., and Nishida T. Nature of the enhancement of lecithin-cholesterol acyltransferase reaction by various apolipoproteins. J. Biol. Chem. 261 (1986) 12028-12035
86. Nishiyama T., Ishizaki F., Anraku T., Shimura H., and Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J. Clin. Endocrinol. Metab. 90 (2005) 657-660
87. Ohta T., Takata K., Horiuchi S., Morino Y., and Matsuda I. Protective effect of lipoproteins containing A-I on Cu2+ catalyzed oxidation of human low-density lipoprotein. FEBS Lett. 257 (1989) 435-438
88. Oswald B., and Quarfordt S. Effect of apoE on triglyceride emulsion interaction with hepatocyte and hepatoma G2 cells. J. Lipid Res. 28 (1987) 798-809
89. Page S.T., Amory J.K., Bowman F.D., Anawalt B.D., Matsumoto A.M., Bremner W.J., and Tenover J.L. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J. Clin. Endocrinol. Metab. 90 (2005) 1502-1510
90. Paigen B., Holmes P.A., Mitchell D., and Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, female and testosterone treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis 64 (1987) 215-221
91. Phillips G.B., Pinkernell B.H., and Jing T.Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler. Thromb. 14 (1994) 701-706
92. Pinthus J.H., Trachtenberg J., and Klotz L. Cardiovascular effects of androgen depletion and replacement therapy. Urology 67 (2006) 1126-1132
93. Plump A.S., Smith J.D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J.G., Rubin E.M., and Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71 (1992) 343-353
94. Plump A.S., Masucci-Magoulas L., Bruce C., Bisgaier C.L., Breslow J.L., and Tall A.R. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 1105-1110
95. Rader D.J. High-density lipoproteins and atherosclerosis. Am. J. Cardiol. 290 (2002) 62-70
96. Rensen P.C., Jong M.C., van Vark L.C., et al. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J. Biol. Chem. 275 (2000) 8564-8571
97. Rosano G.M., Sheiban I., Massaro R., Pagnotta P., Marazzi G., Vitale C., Mercuro G., Volterrani M., Avera A., and Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int. J. Import. Res. 19 (2007) 176-182
98. Saad F., Gooren L., Haider A., and Yassin A. An exploratory study of the effects of 12-month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch. Androl. 53 (2007) 353-357
99. Saad F., Gooren L.J., Haider A., and Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J. Androl. 29 (2008) 102-105
100. Saigal C.S., Gore J.L., Krupski T.L., Hanley J., Schonlau M., Litwin M.S., and And the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110 (2007) 1493-1500
101. Saylor P.J., and Smith M.R. Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol. 181 (2009) 1998-2006
102. Shahani S., Braga-Basaria M., and Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J. Clin. Endocrinol. Metab. 93 (2008) 2042-2049
103. Shahidi N.T. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin. Ther. 23 (2001) 1355-1390
104. Shelburne F., Hanks J., Meyers W., and Quarfordt S. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J. Clin. Invest. 65 (1980) 652-658
105. Shimano H., Ohsuga J., Shimada M., Namba Y., Gotada T., Harada K., Katsuki M., Yazaki Y., and Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J. Clin. Invest. 95 (1995) 469-476
106. Simon D., Charles M.A., Nahoul K., Orssaud G., Kremski J., Hully V., Joubert E., Papoz L., and Eschwege E. Association between plasma testosterone and cardiovascular risk factors in healthy adult men: the Telecom study. J. Clin. Endocrinol. Metab. 82 (1997) 682-685
107. Smith M.R. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr. Urol. Rep. 9 (2008) 197-202
108. Smith M.R., Bennett S., Evans L., Kynaton H., Parmar M., Mason M., Cockcroft J., Scanlon M., and Davies J. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab. 86 (2001) 4261-4267
109. Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A.L., Fallon M.A., Schoenfeld D.A., and Kantoff P.W. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab. 87 (2002) 599-603
110. Smith M.R., Lee H., and Nathan D.M. Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab. 91 (2006) 1305-1308
111. Sparks D.L., and Pritchard P.H. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL lipid and apoprotein content. J. Lipid Res. 30 (1989) 1491-1498
112. Sparrow J.T., and Gotto A.M. Apolipoprotein/lipid interactions: studies with synthetic polypeptides. Crit. Rev. Biochem. 13 (1982) 87-107
113. Stanworth R.D., Kapoor D., and Channer K.S. Testosterone levels correlate positively with HDL cholesterol levels in men with type 2 diabetes. Endocr. Soc. Abstr. 14 (2007) P628
114. Studer U.E., Whelan P., Albrecht W., Casselman J., de Reijke T., Hauri D., Loidl W., Isorna S., Sundaram S.K., Debois M., and Collette L. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J. Clin. Oncol. 24 (2006) 1868-1876
115. Sviridov D., Mukhamedova N., Remaley A.T., Chin-Dusting J., and Nestel P. Antiatherogenic functionality of high-density lipoprotein: how much versus how good. J. Atheroscler. Thromb. 15 (2008) 52-62
116. Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 75 4 (1992) 1092-1098
117. Thompson P.D., Cullinane E.M., Sady S.P., Chenevert C., Saritelli A.L., Sady M.A., and Herbert P.N. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261 (1989) 1165-1168
118. Thorngate F.E., Rudel L.L., Walzem R.L., and Williams D.L. Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1852-1853
119. Tivesten A., Mellström D., Jutberger H., Fagerberg B., Lernfelt B., Orwoll E., Karlsson M.K., Ljunggren O., and Ohlsson C. Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J. Am. Coll. Cardiol. 50 (2007) 1070-1076
120. Tomaszewski M., Charchar F.J., Maric C., Kuzniewicz R., Gola M., Grzeszczak W., Samani N.J., and Zukowska-Szczechowska E. Association between lipid profile and circulating concentrations of estrogens in young men. Atherosclerosis 203 (2009) 257-262
121. Traish A.M., Guay A., Feely R., and Saad F. The dark side of testosterone deficiency I: metabolic syndrome and erectile dysfunction. J. Androl. 30 (2009) 10-22
122. Traish A.M., Saad F., and Guay A. The dark side of testosterone deficiency II: type 2 diabetes and insulin resistance. J. Androl. 30 (2009) 23-32
123. Traish A.M., Guay A., Feely R., and Saad F. The dark side of testosterone deficiency III: vascular disease. J. Androl. 30 (2009) 477-494
124. Trayhurn P., and Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60 (2001) 329-339
125. Tripathy D., Shah P., Lakshmy R., and Reddy K.S. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotropic hypogonadism. Horm. Metab. Res. 30 (1998) 642-645
126. Tsai H.K., D'Amico A.V., Sadetsky N., Chen M.H., and Carroll P.R. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl. Cancer Inst. 99 (2007) 1516-1524
127. Tsompanidi, E.M., Brinkmeier, M.S., Fotiadou, E.H., Giakoumi, S.M., Kypreos, K.E., in press. HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis. Atherosclerosis (Jun 6, Electronic publication ahead of print). PMID: 19595353 (PubMed - as supplied by publisher).
128. Tsukamoto K., Tangirala R., Chun S.H., Pure E., and Rader D.J. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE deficient mice. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 2162-2170
129. Uyanik B.S., Ari Z., Gumus B., Yigitoglu M.R., and Arslan T. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jpn. Heart J. 38 (1997) 73-82
130. Vaidya D., Dobs A., Gapstur S.M., Golden S.H., Hankinson A., Liu K., and Ouyang P. The association of endogenous sex hormones with lipoprotein subfraction profile in the multi-ethnic study of atherosclerosis. Metabolism 57 (2008) 782-790
131. van den Beld A.W., Bots M.L., Janssen J.A., Pols H.A., Lamberts S.W., and Grobbee D.E. Endogenous hormones and carotid atherosclerosis in elderly men. Am. J. Epidemiol. 157 (2003) 25-31
132. van Hinsbergh V.W., Scheffer M., Havekes L., and Kempen H.J. Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim. Biophys. Acta 878 (1986) 49-64
133. van Pottelbergh I., Braeckman L., De Bacquer D., De Baker G., and Kaufman J.M. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in middle aged men. Atherosclerosis 166 (2003) 95-102
134. Vikan T., Johnsen S.H., Schirmer H., Njølstad I., and Svartberg J. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromsø study. Eur. J. Epidemiol. 24 (2009) 289-295
135. von Eckardstein A., Nofer J.R., and Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 13-27
136. Whitsel E.A., Boyko E.J., Matsumoto A.M., Anawalt B.D., and Siscovick D.S. Intramuscular testosterone and plasma lipids in hypogonadal men: a meta-analysis. Am. J. Med. 111 (2001) 261-269
137. Windler E., and Havel R.J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J. Lipid Res. 26 (1985) 556-565
138. Wu F.C., and von Eckardstein A. Androgens and coronary artery disease. Endocr. Rev. 24 (2003) 183-217
139. Yannucci J., Manola J., Garnick M.B., Bhat G., and Bubley G.J. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J. Urol. 176 (2006) 520-525
140. Yeap B.B., Hyde Z., Almeida O.P., Norman P.E., Chubb S.A., Jamrozik K., Flicker L., and Hankey G.J. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J. Clin. Endocrinol. Metab. 94 (2009) 2353-2359
141. Zannis V.I., Kypreos K.E., Chroni A., Kardassis D., and Zanni E.E. Molecular Mechanisms of Atherosclerosis (2004), Taylor & Francis, New York 111-174
142. Zgliczynski S., Ossowski M., Slowinska-Srzednicka J., Brzezinska A., Zgliczynski W., Soszynski P., Chotkowska E., Srzednicki M., and Sadowski Z. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121 (1996) 35-43
143. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 4471-4475
144. Zitzmann M., and Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int. J. Androl. 26 (2003) 76-83
145. Zitzmann M., and Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long term intramuscular testosterone undecanoae therapy in hypogonadal men. J. Clin. Endocrinol. Metab. 92 (2007) 3844-3853
146. Zmuda J.M., Cauley J.A., Kriska A., Glynn N.W., Gutai J.P., and Kuller L.H. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. Am. J. Epidemiol. 146 (1997) 609-617